Turner Parkinson advise SkinBioTherapeutics on IPO

IPO Of Skinbiotherapeutics

Turner Parkinson's Corporate team have advised SkinBioTherapeutics on their listing to AIM.

“This has been a very exciting project for the team at TP, having initially worked with OptiBiotix Health plc in initiating and funding the spin-out of the SkinBiotix technology from the University of Manchester, to helping them achieve the IPO a mere 12 months later.” explained Stephen Hadlow, Corporate Partner. “Partnering fast growing and innovative businesses is a core part of TP’s focus, and the IPO of SkinBioTherapeutics plc is a flagship deal for us. This new investment gives Catherine and her team the scope to further expand and commercialise the technology, and we look forward to supporting the business in the next exciting stage of its development.”

The TP team was led by Head of Corporate James Sheridan who worked alongside colleagues Stephen Hadlow, Louise Chesher and Ryan Tweedale.

This deal was recently covered by Insider.